FDA Action Alert: BMS, Merck, Sanofi/Regeneron and More - BioSpace
The FDA faces several key decisions by September, including Vanda's tradipitant for gastroparesis, Zevra's arimoclomol for Niemann-Pick disease type C, Heron's extended-release needle for Zynrelef, Merck's Keytruda for pleural mesothelioma, and Bristol Myers Squibb's KarXT for schizophrenia. Sanofi and Regeneron seek to expand Dupixent's use for COPD.
Highlighted Terms
bupivacaineBristol Myers SquibbKaruna TherapeuticsKeytrudameloxicamtradipitantVanda Pharmaceuticalschronic obstructive pulmonary diseaseBMSpleural mesotheliomaMerckgastroparesisHeron TherapeuticsZynrelefschizophreniaSanofiFDAZevra TherapeuticsDupixentRegeneronKarXTpembrolizumabNiemann-Pick disease type Carimoclomoldupilumab
Related News
FDA Action Alert: BMS, Merck, Sanofi/Regeneron and More - BioSpace
The FDA faces several key decisions by September, including Vanda's tradipitant for gastroparesis, Zevra's arimoclomol for Niemann-Pick disease type C, Heron's extended-release needle for Zynrelef, Merck's Keytruda for pleural mesothelioma, and Bristol Myers Squibb's KarXT for schizophrenia. Sanofi and Regeneron seek to expand Dupixent's use for COPD.